Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

MindBio Therapeutics Corp. (WF6.F)

Compare
0.0070
0.0000
(0.00%)
As of February 18 at 2:18:05 PM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Justin Adam Hanka Co Founder, CEO & Director 32.58k -- 1973
Mr. John M. Dinan Chief Financial Officer 48.42k -- 1957
Dr. Lahiru Russell Ph.D. Chief Scientist -- -- --

MindBio Therapeutics Corp.

1055 West Georgia Street
1500 Royal Centre P.O Box 11117
Vancouver, BC V6E 4N7
Canada
https://www.mindbiotherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain. In addition, the company develops MB22001, which is in Phase 2 clinical trial, for the treatment of major depressive disorder, as well as existential distress, anxiety, and depression associated with advanced stage cancer; and wearable devices to collect biometric data in mental health patients taking psychedelic medicines. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.

Corporate Governance

MindBio Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.